PTK2 and lung carcinoma: Furthermore, combination of ERK5 and CDK5 inhibition with XMD8-92 and Seliciclib, synergize in suppressing FAK and are expected to prevent feedback signaling leading to drug resistance, providing an additional treatment option for lung cancer patients with KRAS mutations.